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bjectives We compared intravascular ultrasound ﬁndings of drug-eluting stent (DES)–treated le-
ions that developed thrombosis versus in-stent restenosis (ISR).
ackground Stent underexpansion is a predictor of both DES thrombosis and ISR. However, all un-
erexpanded DES may not be equal.
ethods Intravascular ultrasound ﬁndings from 20 deﬁnite DES thrombosis patients (representing
ll deﬁnite thromboses from 1,407 consecutive DES patients undergoing intravascular ultrasound
maging) were compared with 50 risk-factor-balanced ISR patients with no evidence of stent throm-
osis and 50 risk-factor-balanced “no-event” patients with neither thrombosis nor ISR.
esults Minimum stent area (3.9  1.0 mm2 vs. 5.0  1.7 mm2, p  0.008), mean stent area (5.3 
.0 mm2 vs. 7.2  2.0 mm2, p  0.001), and both focal (55.4  13.2% vs. 74.9  19.9%, p  0.001)
nd diffuse stent expansion (77.4  19.3% vs. 109.5  23.1%, p  0.001) were signiﬁcantly smaller
n the stent thrombosis group versus ISR and in both groups versus the “no-event” group. Minimum
tent area 4.0 mm2 (65% vs. 32%, p  0.01) or 5.0 mm2 (85% vs. 52%, p  0.01) was more com-
on in the stent thrombosis versus the ISR group and in both groups vs. “no-event” patients; and
he relative length of the stent area 5 mm2 was greatest in the stent thrombosis group (36.6 
7.7%), intermediate in the ISR group (22.8  35.6%), and least in the “no-event” group (10.9 
6.4%), p  0.04. In the stent thrombosis group, the minimum stent area site occurred in the proxi-
al stent segment in 50% versus 24% in the ISR group (p  0.03). There were no differences in
dge dissection, stent fracture, or stent-vessel-wall malapposition among the groups.
onclusions The DES-treated lesions that develop thrombosis or restenosis are often underex-
anded, but underexpansion associated with thrombosis is more severe, diffuse, and proximal in
ocation. (J Am Coll Cardiol Intv 2009;2:428–34) © 2009 by the American College of Cardiology
oundation
rom the *Columbia University Medical Center and †Cardiovascular Research Foundation, New York, New York.anuscript received September 11, 2008; revised manuscript received December 17, 2008, accepted January 23, 2009.
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429rug-eluting stents (DES) reduce in-stent restenosis (ISR)
nd target lesion revascularization (1–5). With the use of
ual antiplatelet therapy, the frequency of stent thrombosis
s also relatively low (0.4% to 0.6%) (3,4). However, both
ES restenosis and thrombosis occur with greater fre-
uency during routine, clinical, “real-world” procedures
han in randomized trials (6,7). Although intravascular
ltrasound (IVUS) studies have identified DES underex-
ansion as a predictor of both restenosis and thrombosis
7–9), no study has compared IVUS findings in DES
hrombosis versus DES restenosis to understand whether
See page 435
atterns of stent underexpansion are similar or different in
hese 2 groups. The aim of the current study was to compare
VUS findings of patients with DES-treated lesions who
eveloped stent thrombosis versus a matched group of DES-
reated lesions that subsequently developed ISR and both
roups with matched control patients in an attempt to discover
hy some underexpanded stents thrombose and others rest-
nose. Are all underexpanded DES the same? Or is there an
VUS explanation why some thrombose and others restenose?
ethods
atient population. During the 39-month study period
October 2004 through December 2007), we identified
,407 consecutive patients who underwent sirolimus-eluting
tent (Cypher, Cordis, Miami Lakes, Florida) (74%) or
aclitaxel-eluting stent (Taxus, Boston Scientific, Maple
rove, Minnesota) (26%) implantation at Columbia Uni-
ersity Medical Center in whom IVUS was performed at
he time of the original interventional procedure and/or at
he time of stent thrombosis or ISR or scheduled event-free
ollow-up. The IVUS findings in this group of patients have
ot been reported although our group has previously per-
ormed and reported similar analyses in other groups of
atients treated at other institutions.
Baseline demographic and procedural variables of all
,407 patients were recorded and entered prospectively into
pre-specified database by a dedicated data-coordinating
enter. This study was approved by the institutional review
oard; written informed consent was obtained from all
atients.
All patients were pre-medicated with 325 mg of aspirin
hat was continued indefinitely. A loading dose of 600 mg of
lopidogrel was administered in the catheterization labora-
ory, and clopidogrel 75 mg/day was recommended for 12
onths after the procedure. At the beginning of the
rocedure, a bolus of bivalirudin was administered at a dose
f 0.75 mg/kg to achieve an activated clotting time 250 s
ollowed by intravenous bivalirudin at 1.75 mg/kg/h. Gly- Moprotein IIb/IIIa inhibitors were used electively (and in-
requently) at the discretion of the operator.
All “definite” stent thrombosis patients were included in
he current analysis. According to the Academic Research
onsortium, “definite” stent thrombosis was an acute cor-
nary syndrome with angiographic evidence of thrombus or
cclusion. Stent thrombosis was categorized as early (0 to 30
ays), late (31 to 360 days), or very late (360 days) (10).
Fifty ISR patients without stent thrombosis were then
dentified. These ISR patients were risk-factor-balanced
ersus stent thrombosis patients by: 1) DES type; 2)
iabetes; 3) coronary artery; 4) bifurcation lesion location;
nd 5) reference external elastic membrane (EEM) cross-
ectional area (CSA). In-stent restenosis was defined as an
ngiographic diameter stenosis of 50%.
Finally, using the same criteria, we identified a consecu-
ive series of 50 patients without any evidence of DES
hrombosis or restenosis who underwent routine angio-
raphic and IVUS follow-up.
VUS imaging and analysis. All IVUS studies were per-
ormed after the intracoronary administration of 0.1 to 0.2
g nitroglycerin using only 1
ype of commercially available
VUS system (Boston Scientific,
remont, California). The
VUS catheter was advanced
10 mm distal to the lesion, and
maging was performed through
he stent to the proximal refer-
nce at an automatic pullback
peed of 0.5 mm/s. The IVUS
ata were recorded onto a high-
esolution, half-inch, s-VHS
ape or digital media for later offline analysis.
Stent malapposition was the lack of contact between any
trut and the underlying vessel wall. Dissection was a tear in
he plaque parallel to the vessel wall with visualization of
lood flow in the false lumen (confirmed, if necessary, with
aline or contrast injection). Stent fracture was the absence
f stent struts for at least one-third of the stent circumfer-
nce in 1 frame.
Using planimetry software (EchoPlaque, INDEC Sys-
ems, Mountain View, California), measurements of EEM,
umen, plaque and media ( EEM  lumen), and stent
SA were performed every 1 mm within the stent and
roximal and distal reference segments. Plaque burden was
laque and media CSA divided by EEM CSA. Volumes
ere calculated using Simpson’s rule and normalized for
tent length. Proximal and distal reference segment mea-
urements included: 1) least-diseased image slices (maxi-
um lumen with least plaque); and 2) most-diseased image
lices (smallest lumen and greatest plaque) proximal and
istal to the stent edge, but before any major side branch.
Abbreviations
and Acronyms
CSA  cross-sectional area
DES  drug-eluting stent(s)
EEM  external elastic
membrane
ISR  in-stent restenosis
IVUS  intravascular
ultrasound
MSA  minimum stent areaean reference lumen CSA was the average of proximal
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430nd distal “least-diseased” reference lumen CSAs. Focal
tent expansion was minimum stent area (MSA) divided by
ean reference lumen CSA. Diffuse stent expansion was
ean stent CSA divided by mean reference lumen CSA.
tent symmetry was maximum stent diameter divided by
inimum stent diameter at MSA site. Axial stent symmetry
as maximum stent CSA divided by minimum stent CSA.
tatistics. Statistical analysis was performed using SPSS
1.5 (SPSS Inc., Chicago, Illinois). Continuous variables
ere presented as mean  SD and compared using analysis
f variance with post-hoc analysis using the Bonferroni
orrection. Categorical data were compared using chi-
quare statistics or Fisher exact test. P values 0.05 were
onsidered statistically significant except for post-hoc anal-
sis when 0.017 (0.05 divided by 3) was required for
ignificance.
esults
atients and procedures. Twenty patients with angiography-
onfirmed stent thrombosis (17 Cypher stents and 3 Taxus
tents) had IVUS imaging at the time of stent thrombosis (n
4), at the time of stent implantation (n 2), or both (n 4).
eventeen (85%) had early stent thrombosis, and 3 (15%) had
ate stent thrombosis; none had very late stent thrombosis. The
edian time between the index procedure and the thrombotic
vent was 9.0 days. Fifty-three percent (9 of 17) of the early
ases occurred1 week from the index procedure; and 67% (2
f 3) of the late thrombosis cases occurred6 months from the
ndex procedure.
Table 1. Baseline Clinical and Angiographic Characteristics
Stent Thrombosis
(n  20)
Age, yrs 62.4 11.2
Male 11 (55)
Diabetes 9 (45)
Hypertension 16 (80)
Hyperlipidemia 17 (85)
Smoking 5 (25)
Previous myocardial infarction 6 (30)
Unstable angina 8 (40)
Stent implanted
Sirolimus-eluting stent 17 (85)
Paclitaxel-eluting stent 3 (15)
Target coronary artery
Left anterior descending artery 12 (60)
Left circumﬂex artery 3 (15)
Right coronary artery 5 (25)
Bifurcation lesion 5 (25)
Creatinine, mg/dl 1.2 0.7
Continuous variables are presented as mean 1 SD or n (%).ISR in-stent restenosis.Of the 50 ISR patients, 35 had IVUS imaging only at the
ime of ISR, whereas 15 patients had IVUS imaging both at
he time of stent implantation and ISR. The median time
etween index and ISR was 8.3 months.
Of the 50 control patients, 34 had IVUS imaging only at
he time of scheduled follow-up, and 16 patients had IVUS
maging both at the time of stent implantation and follow-
p. The median time between index and event-free
ollow-up was 8.1 months.
There were no significant differences among stent throm-
osis, ISR, and no-event groups regarding baseline clinical
nd angiographic characteristics (Table 1). In the stent
hrombosis group, 11 lesions (55%) were treated with 1
tent; 6 lesions (30%) with 2 stents; and 3 lesions (15%) with
stents. In the ISR group, 27 lesions (54%) were treated
ith 1 stent; 19 lesions (38%) with 2 stents; and 4 lesions
8%) with 3 stents. In the no-event group, 34 lesions (68%)
ere treated with 1 stent; 12 lesions (24%) with 2 stents;
nd 4 lesions (8%) with 3 stents. None of the stent
hrombosis patients stopped dual antiplatelet therapy pre-
aturely.
VUS ﬁndings. The IVUS findings are presented in Table 2.
lthough reference EEM and proximal or distal reference
umen CSAs tended to be larger, MSA (3.9  1.0 mm2 vs.
.0  1.7 mm2, p  0.008), minimum stent diameter (1.9
0.3 mm vs. 2.3  0.4 mm, p  0.001), and mean stent
SA (5.3  1.0 mm2 vs. 7.2  2.0 mm2, p  0.001) were
ignificantly smaller in stent thrombosis patients than in
SR patients (see Fig. 1 for individual patient data).
ISR
(n  50)
No Events
(n  50) p Value
59.9 11.8 62.9 9.3 0.46
36 (72) 36 (72) 0.32
22 (44) 26 (52) 0.70
43 (86) 40 (80) 0.70
45 (90) 42 (84) 0.66
22 (44) 22 (44) 0.25
19 (38) 10 (20) 0.14
20 (40) 11 (22) 0.12
0.83
40 (80) 42 (84)
10 (20) 8 (16)
0.96
33 (66) 32 (64)
5 (10) 7 (14)
12 (24) 11 (22)
10 (20) 7 (14) 0.52
1.2 0.4 1.2 0.5 0.98
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431The MSA was located in the proximal half of the stent in
0 of 20 stent thrombosis lesions versus 12 of 50 ISR lesions
p  0.03).
Overall, 13 of 20 (65%) stent thrombosis lesions had an
SA 4.0 mm2 versus 16 of 50 (32%) ISR lesions versus
of 50 (12%) no-event lesions (p  0.001). Overall, 17 of
0 (85%) stent thrombosis lesions had an MSA 5.0 mm2
ersus 26 of 50 (52%) ISR lesions versus 13 of 50 (26%)
o-event lesions (p  0.001). When stent CSA was
ompared with the reference lumen, focal stent expansion
Table 2. IVUS Findings Comparing Stent Thrombosis Versus ISR Versus No
Stent Thrombosis
(n  20)
ISR
(n  50)
Stents per lesion 1.6 0.8 1.5 0.6
Stent length, mm 31.9 13.2 30.9 17.
Reference segment
Least diseased image slice
EEM CSA, mm2 13.4 3.6 12.2 4.2
Proximal lumen CSA, mm2 8.0 1.8 7.5 2.4
Distal lumen CSA, mm2 6.0 2.6 5.6 1.9
Proximal plaque burden, % 49.0 14.4 44.8 14.
Distal plaque burden, % 42.0 19.4 41.8 12.
Most diseased image slice
EEM CSA, mm2 13.5 3.8 11.6 4.5
Proximal lumen CSA, mm2 6.5 1.5 6.9 2.6
Distal lumen CSA, mm2 5.2 2.6 5.2 1.7
Proximal plaque burden, % 57.4 14.9 47.2 15.
Distal plaque burden, % 46.7 19.0 44.9 13.
Stent segment
Maximum stent CSA, mm2 8.4 2.4 9.1 2.8
MSA, mm2 3.9 1.0 5.0 1.7
Mean stent CSA, mm2 5.3 1.0 7.2 2.0
Maximal stent diameter, mm 3.5 0.5 3.7 0.6
Minimal stent diameter, mm 1.9 0.3 2.3 0.4
Stent symmetry 1.3 0.4 1.2 0.1
Axial stent symmetry 2.2 0.8 1.9 0.5
Focal stent expansion, % 55.4 13.2 74.9 19.
Diffuse stent expansion, % 77.4 19.3 109.5 23.
Proximal/distal MSA site 10/10 12/38
MSA 50% reference lumen 6 (30) 2 (4)
MSA 60% reference lumen 13 (65) 13 (26)
MSA 70% reference lumen 16 (80) 24 (48)
MSA 80% reference lumen 19 (95) 32 (64)
MSA 4.0 mm2 13 (65) 16 (32)
MSA 5.0 mm2 17 (85) 26 (52)
Mean stent CSA 6.0 mm2 17 (85) 13 (26)
Stent malapposition at follow-up 9 (45) 20 (40)
Stent fracture 1 (5) 1 (2)
Stent in stent 0 (0) 8 (16)
Continuous variables are presented as mean 1 SD or n (%). Post-hoc P1: stent thrombosis versus
ANOVA analysis of variance; CSA cross-sectional area; EEM external elastic membrane; MSeasured 55.4  13.2% in stent thrombosis patients versus t4.9  19.9% in ISR patients versus 79.0  17.8% in
o-event patients (p  0.001); and diffuse stent expansion
easured 77.4  19.3% in stent thrombosis patients versus
09.5  23.1% in ISR patients versus 100.0  18.0% in
o-event patients (p  0.001). Focal stent expansion and
iffuse stent expansion for DES thrombosis, restenosis, and
o-event groups are shown in Figure 2.
The relative length of the stented segment with a stent
rea 4 mm2 (14.3  21.0% vs. 13.5  27.7% vs. 3.2 
0.1%, analysis of variance of p  0.06) were similar among
t
No Event
(n  50)
ANOVA
p Value P1 P2 P3
1.4 0.6 0.4 — — —
25.5 16.7 0.3 — — —
12.7 3.7 0.5 — — —
8.3 2.2 0.3 — — —
7.2 2.4 0.004 0.5 0.08 0.001
36.4 16.5 0.01 0.4 0.01 0.06
35.4 13.8 0.1 — — —
12.0 3.5 0.2 — — —
7.7 2.4 0.3 — — —
6.2 2.1 0.1 — — —
38.7 17.8 0.001 0.04 0.001 0.02
41.0 14.7 0.3 — — —
9.9 2.4 0.1 — — —
6.0 1.6 0.001 0.008 0.001 0.002
7.6 1.7 0.001 0.001 0.001 0.3
3.9 0.5 0.03 0.2 0.01 0.1
2.5 0.4 0.001 0.001 0.001 0.006
1.2 0.1 0.009 0.005 0.004 0.9
1.7 0.5 0.003 0.03 0.001 0.1
79.0 17.8 0.001 0.001 0.001 0.3
100.0 18.0 0.001 0.001 0.001 0.04
10/40 0.03 0.03 0.01 0.6
3 (6) 0.002 0.002 0.007 0.6
6 (12) 0.001 0.002 0.001 0.07
12 (24) 0.001 0.02 0.001 0.01
27 (54) 0.005 0.008 0.001 0.3
6 (12) 0.001 0.01 0.001 0.02
13 (26) 0.001 0.01 0.001 0.008
9 (18) 0.001 0.001 0.001 0.3
18 (36) 0.8 — — —
0 (0) 0.3 — — —
4 (8) 0.1 — — —
tent thrombosis versus no event; P3: ISR versus no event.
nimum stent area; other abbreviations as in Table 1.Even
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432owever, the relative length of the stented segment with a
tent area5 mm2 was greatest in stent thrombosis patients
36.6  37.7%), intermediate in ISR patients (22.8 
5.6%), and least in no-event patients (10.9  26.4%),
nalysis of variance of p  0.03.
Stent asymmetry was greater in stent thrombosis patients
han in ISR patients and no-event patients. However, there
as no significant difference in edge dissection, stent frac-
ure, or late stent-vessel wall malapposition among the 3
roups. There was 1 distal stent edge (type B angiographic)
issection in the stent thrombosis group; this patient devel-
ped stent thrombosis 2 days after stent implantation. Two
tent fractures (both in the right coronary artery) were
oted, 1 in the stent thrombosis group and another in the
SR group.
The IVUS findings were similar when only the Cypher
tents were analyzed or compared with Taxus stents and
hen only early stent thrombosis cases were analyzed or
ompared with late stent thrombosis.
iscussion
revious studies—including reports from our group using
otally different patient cohorts—have shown that stent
nderexpansion is a consistent finding with bare-metal stent
nd DES thrombosis and restenosis (8,9,11–17). The
resent study confirmed the importance of stent underex-
ansion and extended this observation to show that under-
xpansion may be more severe, more diffuse, and more often
Figure 1. Distribution of Minimum and Mean Stent Areas
Individual values comparing minimum and mean stent areas for drug-
eluting stent (DES) thromboses, restenoses, and no-event groups are
shown (open squares  DES thrombosis, solid squares  DES restenosis,
and open triangles  no event). CSA  cross-sectional area; MSA  mini-
mum stent area.roximal in DES that thrombose versus those that re-tenose. Conversely, the present study did not show any
ther quantitative or qualitative grayscale IVUS features
eparating these 2 DES-related complications including
trut fracture and stent-vessel wall malapposition.
Atherosclerosis, neointimal hyperplasia, and stent throm-
osis predominantly develop at sites of low wall shear stress
18–20). Sukavaneshvar et al. (21) have demonstrated that
ncreased radial transport of blood components and low wall
hear stress promote platelet-dependent thrombosis. Ac-
ording to Hagen-Poiseuille law, wall shear stress is in-
ersely proportional to the cube of the radius. However,
specially when assessing thrombus formation, precise in-
rastent “local” wall shear stress is more complicated and
ependent on 3-dimensional anatomical characteristic of
he stent in relation to the intravascular blood flow velocity
rofile as well as the geometry of stent inflow. Most
revious in vivo studies neglected 3-dimensional stent
xpansion characteristics such as underexpanded stent seg-
ent length, axial stent symmetry, site of maximum stent
nderexpansion, and overall stent volume; these may affect
lood flow and lead to stent thrombosis or neointimal
yperplasia. In the present study, the 3-dimensional char-
cteristics of the stent—mean stent area, diffuse stent
nderexpansion, and upstream location of the MSA site—
est differentiated thrombosis patients from ISR patients.
revious studies showed that inflow/outflow disease was a
isk factor for restenosis or thrombosis, and that residual
eference segment stenosis was associated with stent throm-
osis (8,21).
Stent underexpansion is common despite systematic use
f high-pressure inflations and modern stent designs, but
he incidence of stent thrombosis and ISR remain relatively
Figure 2. Comparison of Stent Expansion
Focal stent expansion and diffuse stent expansion (both mean  1 SD)
for drug-eluting stent thromboses, restenoses, and no-event groups are
shown. ISR  in-stent restenosis.
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433ow. Thus, mechanical problems resulting in a suboptimal
tent deployment cannot explain all cases of stent throm-
osis. In addition, predictors of stent thrombosis also
nclude diabetes, low left ventricular ejection fraction, renal
ailure, bifurcation lesion locations, and premature discon-
inuation of antiplatelet therapy—clinical factors typically
nrelated to stent underexpansion (6,10,22–26).
Delayed endothelialization associated with DES implan-
ation may extend the risk of thrombosis beyond 30 days.
evertheless, 17 of our 20 DES thrombosis patients had
heir events within 30 days.
Mechanical factors (such as underexpansion) are probably
ore important in early DES thrombosis, whereas biologic
actors are more important in late DES thrombosis, espe-
ially very late DES thrombosis. Other nonmechanical
auses of DES thrombosis may include inflammation,
ypersensitivity, poor vessel wall healing, strut penetration
nto a necrotic core, and aneurysm formation (27). There
as been a recent focus on very late post-DES thrombosis
28). In a study of 13 patients (8 Cypher and 5 Taxus) with
ery late (12 months) stent thrombosis, the predominant
VUS finding was incomplete stent-vessel wall apposition
veraging 8 mm2 in CSA in 10 of 13 patients (29).
ncomplete stent apposition occurs as a result of positive
emodeling and has been associated with lack of stent
e-endothelialization (30). In our study, stent malapposition
id not differentiate DES thrombosis from restenosis from
ontrols, but we had few cases of late DES thrombosis and
o cases of very late DES thrombosis. Given that 85% of
ur DES thrombosis events occurred within 30 days and
hat the median time to thrombosis in these 17 patients was
.0 days, it is unlikely that positive remodeling would have
ccurred in so short a time. Therefore, stent malapposi-
ion at the time of the event most likely persisted from
mplantation.
Minimum stent area is also a major predictor of clinical,
ngiographic, or IVUS DES restenosis. Once intimal hy-
erplasia is suppressed, the impact of MSA becomes mag-
ified. In a substudy of the SIRIUS (Sirolimus-Eluting
tent in Coronary Lesions) trial, the post-intervention
SA that best separated “adequate” from “inadequate”
atency was 5.0 mm2 with a positive predictive value of 90%
15). The present study further confirmed the importance of
SA as a contribution to DES restenosis, but suggested
hat underexpansion in DES restenosis is more focal and
ore distal.
Unlike previous reports, a significant residual edge plaque
urden or longitudinal geographical miss did not predict
ES edge restenosis or thrombosis (8,17,31). The current
nalysis was performed on patients treated after the rela-
ionship between uncovered inflow/outflow disease and
tent thrombosis and was identified leading to more com-
lete lesion coverage.tudy limitations. This was a retrospective study. However,
espite the recent focus on DES thrombosis, this compli-
ation is uncommon; most IVUS series contain few pa-
ients; and most cases of DES thrombosis do not have
VUS evaluation. Of the 20 stent thrombosis patients, 4
ere imaged both at the time of stent implantation and
tent thrombosis, 14 were imaged only at the time of stent
hrombosis, and 2 were imaged only at implantation;
ecause imaging was not done in a uniform fashion, this
ight have introduced some bias. However, 18 of 20 were
maged at the time of thrombosis, and stents do not recoil
fter implantation. We were not able to assess the reasons
or stent underexpansion in these patients, and we do not
now the overall denominator of patients with stent under-
xpansion. The current findings do not apply to patients
ith very late (1 year) stent thrombosis; 85% had early
tent thrombosis (1 month), 15% had late stent throm-
osis (1 month to 1 year), and none had very late stent
hrombosis. Finally, it is likely that there are still many
actors—including, for example, delayed endothelialization,
essel wall pathology, poor responsiveness to dual antiplate-
et therapy—that cannot be assessed using IVUS, but that
re important contributors to stent thrombosis.
onclusions
lthough stent underexpansion contributes to both DES
hrombosis and restenosis, the current study suggests that
ot all underexpanded DES are equal and that there is a
ifference between underexpanded stents that thrombose
ersus underexpanded stents that restenose. Underexpan-
ion in DES that thrombose is more severe, more diffuse,
nd more often proximal in location.
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